by in
Entry Author Date Location
Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal 03/18/13 San Francisco
Has The Pendulum Swung Too Far in Favor of Rare Diseases? 03/14/13 Seattle
Some Bold Baseball and Biotech Picks for the 2013 Season 03/11/13 National
East Coast Life Sciences Roundup: Merck, Celgene, PTC, Cerulean 03/08/13 Boston
Roger Perlmutter Returns to Merck, Looks to Biotech Future (Again) 03/07/13 New York
Corporate Compliance Programs: The Importance of Being Effective 02/15/13 National
Ironwood Bucks the Trends, Makes Big Bet on Drug For Millions 02/06/13 Boston
Alnylam Gets $25M From Medicines Co. for Cholesterol Drug 02/04/13 Boston
Keryx Finally Succeeds With a Clinical Trial, for Kidney Disease Drug 01/28/13 New York
Alder Biopharma Looks to Take On Migraines, and the World 01/24/13 Seattle
VenBio’s Goodman Builds an Inside Periscope on Biotech Acquisitions 01/23/13 San Francisco
The Intersection of the Double Helix and Life Sciences in Seattle 01/22/13 Seattle
Boston’s Got Big Mo in Biotech, But SF is Pushing Back 01/21/13 National
East Coast Life Sciences Roundup: Bind, Boston Children’s, J&J, More 01/11/13 Boston
Mid-Priced Biotechnology Companies Bloom As M&A Targets in 2013 01/10/13 San Francisco
BIND CEO Says Amgen Deal Marks Nanomedicine Turning Point 01/09/13 Boston
Amgen in $180.5 Million Drug Development Deal with BIND Biosciences 01/08/13 Boston
My Report Card for JP Morgan Healthcare Conference Picks 01/07/13 National
Crescendo Bioscience Snags $28M For Arthritis Test 01/03/13 San Francisco
East Coast Life Sciences Roundup: Ariad, Celgene, Amgen, More 12/14/12 Boston
The Road to Predictable Innovation: Genomics in Drug R&D 12/10/12 Boston
Amgen Acquires DeCode Genetics, the Once-Fallen Star, for $415M 12/10/12 National
Where’s the Can-Do Spirit in Biotech? It’s Alive, Deep Down 12/03/12 National
Xconomist of the Week: NPS’s Francois Nader Shares Lessons Learned 10/25/12 New York
Celgene Puts $35M into VentiRx, Gets Option to Buy Cancer Drugmaker 10/03/12 Seattle
The Reproducibility Initiative: A Good Idea in Theory that Won’t Work in Practice 10/02/12 Seattle
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Bayer, Onyx Cancer Drug Wins FDA Approval Ahead of Schedule 09/27/12 San Francisco
Zymeworks Hits Antibody Drug Milestone For Merck, Raises $11M 09/06/12 Seattle
Would Longer Drug Patents Really Lead to Lower Drug Prices? 09/05/12 Seattle
Page 3 of 13 « previous page · next page »